The state urge to be physically active in anorexia nervosa: a systematic review of mechanisms and clinical implications.

J Psychiatr ResJun 13, 2026 (epub)
Clinical ResearchPsychiatryInternal Medicine (General)

Margherita Boltri, Carolina Gabutti, Lara Pignattai et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the State Urge to be Physically Active (SUPA) in individuals with anorexia nervosa (AN), analyzing 17 studies. It found that SUPA persists regardless of BMI changes and may serve as a maladaptive emotion regulation strategy. Higher SUPA levels during weight restoration predict poorer post-treatment weight maintenance.

Key findings

  • SUPA may persist regardless of BMI changes, including during recovery.
  • Higher SUPA levels during weight restoration predict poorer post-treatment weight maintenance.
  • SUPA functions as a maladaptive emotion regulation strategy rather than a dispositional feature.

Why it matters

Understanding SUPA in anorexia nervosa is crucial for clinicians, as it may indicate illness severity and resistance to treatment, influencing management strategies and patient outcomes.

Source

PubMed · PMID 42314357

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.